Pacritinib was designed as a JAK2 and FLT3 inhibitor with the goal of developing a drug to target hematological malignancies driven by these kinases including myelofibrosis, lymphoma, and acute myeloid leukemia (AML)28. The gene discussed is FLT3; the disease is myelofibrosis.